查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1747292

副甲状腺疾病市场按类型、疾病类型、给药途径、年龄层、性别、最终用户、分销管道和地区划分

Parathyroid Disorders Market, By Type, By Disorder Type, By Route of Administration, By Age Group, By Gender, By End User, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计 2025 年全球甲状旁腺疾病市场规模为 111 亿美元，到 2032 年将达到 139.3 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 3.3%。

报告范围 报告详细信息
基准年 2024 2025年的市场规模 111亿美元
效能数据 从2020年到2024年 预测期 2025年至2032年
预测期：2025-2032年复合年增长率： 3.30% 2032年价值预测 139.3亿美元

近年来，全球甲状旁腺疾病市场显着成长，这得益于副甲状腺疾病盛行率的上升、诊断技术的进步以及新型治疗方案的开发。副甲状腺疾病包括副甲状腺机能亢进症和甲状旁腺功能低下症，其特征是副甲状腺功能异常，导致体内钙和磷酸盐失衡。这些疾病会严重影响骨骼健康、心血管功能和整体生活品质。随着人们对副甲状腺疾病认识的不断提高以及先进治疗方法的普及，预计全球甲状旁腺疾病市场在预测期内将显着增长。

市场动态：

全球副甲状腺疾病市场受多种因素驱动，例如副甲状腺疾病盛行率的上升，尤其是原发性副甲状腺功能亢进症，这种疾病在停经后女性中原发性副甲状腺机能亢进症。此外，老年人口的成长也更容易罹患副甲状腺疾病，预计也将刺激市场成长。诊断技术的进步，例如改进的影像技术和基因检测，使得副甲状腺疾病的早期发现和准确诊断成为可能，进一步推动了市场成长。此外，标靶治疗和微创手术等新型治疗方法的开发，扩大了治疗选择，并改善了患者的预后。然而，治疗费用高昂、某些地区对副甲状腺疾病的认知度有限以及某些治疗方法的潜在副作用等因素可能会抑制市场成长。儘管存在这些限制因素，但对研发活动的日益重视、行业参与者与学术机构之间的合作以及甲状旁腺疾病领域个性化医疗方法的兴起，正在为市场带来巨大的增长机会。

本研究的主要特点

  • 本报告对全球甲状旁腺疾病市场进行了详细分析，并给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），假设基准年为 2024 年。
  • 它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
  • 它根据公司亮点、产品系列、关键亮点、业绩和策略等参数列出了全球副甲状腺疾病市场的主要企业简介。
  • 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
  • 本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 可以透过用于分析全球甲状旁腺疾病市场的各种策略矩阵来促进相关人员的决策。

    目录

第一章 调查目的与前提条件

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要

第三章市场动态、法规与趋势分析

  • 市场动态
  • 驱动程式
  • 限制因素
  • 机会
  • 影响分析
  • 主要进展
  • 监管情景
  • 产品发布/核准
  • PEST分析
  • 波特分析
  • 併购场景
  • 产业趋势

4. 2020 年至 2032 年全球甲状旁腺疾病市场（按类型）

  • 药物类别
  • 副甲状腺素（PTH）类似物
  • 双磷酸盐
  • 钙兴奋剂
  • 维生素 D 类似物
  • 磷酸盐粘合剂
  • 诊断方法
  • 血液检查
  • 影像技术
  • 尿液检查

5. 全球副甲状腺疾病市场（依疾病类型），2020-2032 年

  • 原发性副甲状腺机能亢进症
  • 次发性副甲状腺机能亢进
  • 三发性副甲状腺机能亢进症
  • 甲状旁腺功能低下症

6. 全球副甲状腺疾病市场（依给药途径），2020 年至 2032 年

  • 口服
  • 肠外

7. 全球副甲状腺疾病市场（依年龄族群划分），2020 年至 2032 年

  • 孩子们
  • 成人
  • 老年人

8. 2020 年至 2032 年全球副甲状腺疾病市场（依性别划分）

  • 男人
  • 女士

9. 全球副甲状腺疾病市场（依最终用户划分），2020 年至 2032 年

  • 医院
  • 专科诊所
  • 门诊中心
  • 研究所
  • 诊断中心
  • 家庭医疗保健

第 10 章。全球甲状旁腺疾病市场（按分销管道划分），2020-2032 年

  • 医院药房
  • 零售药局
  • 网路药局

第 11 章。 2020-2032 年按地区分列的全球副甲状腺疾病市场

  • 北美洲
      • 美国
      • 加拿大
  • 拉丁美洲
      • 巴西
      • 阿根廷
      • 墨西哥
      • 其他拉丁美洲
  • 欧洲
      • 德国
      • 英国
      • 西班牙
      • 法国
      • 义大利
      • 俄罗斯
      • 其他欧洲国家
  • 亚太地区
      • 中国
      • 印度
      • 日本
      • 澳洲
      • 韩国
      • ASEAN
      • 其他亚太地区
  • 中东
      • 海湾合作委员会国家
      • 以色列
      • 其他中东地区
  • 非洲
      • 南非
      • 北非
      • 中部非洲

第十二章竞争格局

  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sandoz（a Novartis division）
  • Otsuka Pharmaceutical Co., Ltd.

第 13 章分析师建议

  • 机会
  • 分析师观点
  • Coherent Opportunity Map

第十四章参考文献与调查方法

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI7966

Global Parathyroid Disorders Market is estimated to be valued at USD 11.10 Bn in 2025 and is expected to reach USD 13.93 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.3% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 11.10 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 3.30% 2032 Value Projection: USD 13.93 Bn

The global parathyroid disorders market has witnessed significant growth in recent years, driven by the increasing prevalence of parathyroid disorders, advancements in diagnostic techniques, and the development of novel treatment options. Parathyroid disorders, which include hyperparathyroidism and hypoparathyroidism, are characterized by abnormal functioning of the parathyroid glands, leading to imbalances in calcium and phosphate levels in the body. These disorders can have severe consequences on bone health, cardiovascular function, and overall quality of life. With the rising awareness about parathyroid disorders and the availability of advanced treatment modalities, the global parathyroid disorders market is expected to experience substantial growth during the forecast period.

Market Dynamics:

The global parathyroid disorders market is driven by several factors, including the increasing prevalence of parathyroid disorders, particularly primary hyperparathyroidism, which is more common in postmenopausal women. Additionally, the growing geriatric population, which is more susceptible to parathyroid disorders, is expected to fuel market growth. Advancements in diagnostic techniques, such as improved imaging modalities and genetic testing, have enabled early detection and accurate diagnosis of parathyroid disorders, further driving market growth. Moreover, the development of novel treatment options, including targeted therapies and minimally invasive surgical procedures, has expanded the treatment landscape and improved patient outcomes. However, the market growth may be restrained by factors such as the high cost of treatments, limited awareness about parathyroid disorders in certain regions, and the potential side effects associated with some treatment options. Despite these restraints, the market presents significant opportunities for growth, driven by the increasing focus on research and development activities, collaborations between industry players and academic institutions, and the emergence of personalized medicine approaches in the field of parathyroid disorders.

Key Features of the Study:

  • This report provides in-depth analysis of the global parathyroid disorders market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global parathyroid disorders market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Regeneron Pharmaceuticals, Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Sandoz (a Novartis division), and Otsuka Pharmaceutical Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global parathyroid disorders market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global parathyroid disorders market

Market Segmentation

  • Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Drug Class
    • Parathyroid Hormone (PTH) Analogues
    • Bisphosphonates
    • Calcimimetics
    • Vitamin D Analogues
    • Phosphate Binders
    • Diagnostic Method
    • Blood Tests
    • Imaging Techniques
    • Urine Tests
  • Disorder Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Primary Hyperparathyroidism
    • Secondary Hyperparathyroidism
    • Tertiary Hyperparathyroidism
    • Hypoparathyroidism
  • Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
    • Oral
    • Parenteral
  • Age Group Insights (Revenue, USD Bn, 2020 - 2032)
    • Pediatric
    • Adult
    • Geriatric
  • Gender Insights (Revenue, USD Bn, 2020 - 2032)
    • Male
    • Female
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals
    • Specialty Clinics
    • Outpatient Centers
    • Research Institutes
    • Diagnostic Centers
    • Home Healthcare
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Amgen Inc.
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi S.A.
    • Bristol-Myers Squibb Company
    • AbbVie Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Astellas Pharma Inc.
    • Takeda Pharmaceutical Company Limited
    • Sandoz (a Novartis division)
    • Otsuka Pharmaceutical Co., Ltd.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Parathyroid Disorders Market, By Type
    • Global Parathyroid Disorders Market, By Disorder Type
    • Global Parathyroid Disorders Market, By Route of Administration
    • Global Parathyroid Disorders Market, By Age Group
    • Global Parathyroid Disorders Market, By Gender
    • Global Parathyroid Disorders Market, By End User
    • Global Parathyroid Disorders Market, By Distribution Channel
    • Global Parathyroid Disorders Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Parathyroid Disorders Market, By Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Drug Class
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Parathyroid Hormone (PTH) Analogues
  • Bisphosphonates
  • Calcimimetics
  • Vitamin D Analogues
  • Phosphate Binders
  • Diagnostic Method
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Blood Tests
  • Imaging Techniques
  • Urine Tests

5. Global Parathyroid Disorders Market, By Disorder Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Primary Hyperparathyroidism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Secondary Hyperparathyroidism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Tertiary Hyperparathyroidism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Hypoparathyroidism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Parathyroid Disorders Market, By Route of Administration, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Parathyroid Disorders Market, By Age Group, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Parathyroid Disorders Market, By Gender, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Male
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Female
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Parathyroid Disorders Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Outpatient Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Research Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Diagnostic Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Home Healthcare
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Parathyroid Disorders Market, By Distribution Channel, 202-02032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Parathyroid Disorders Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

12. Competitive Landscape

  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Regeneron Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Astellas Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sandoz (a Novartis division)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Otsuka Pharmaceutical Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

13. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

14. References and Research Methodology

  • References
  • Research Methodology
  • About us